1159. Meet-the-Professor
Session: Mini-Symposium: Antimicrobial Pharmacodynamics in Clinical Practice
Saturday, October 5, 2013: 7:35 AM
Room: The Moscone Center: Esplanade Ballroom 301-310
Thomas Lodise, Pharm D, Albany College of Pharmacy and Health Sciences, Albany, NY

Dr. Thomas Lodise is an Associate Professor at Albany College of Pharmacy and Health Sciences, Albany, New York. Dr. Lodise, a 1999 summa cum laude doctor of pharmacy graduate of Temple University School of Pharmacy, joined the faculty at Albany College of Pharmacy in August 2002. Prior to Albany College of Pharmacy, he completed the APhA-ASHP–accredited Pharmacy Practice Residency at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania in 2000 and the Infectious Diseases Pharmacotherapy and Outcomes Fellowship at Wayne State University, Detroit, Michigan in 2002. Integrating his dual interests in research and patient care, his current research focuses on the epidemiology and outcomes of bacterial infections, and his work explores antibiotic exposure-response relationships among patients. His specific objectives are 3-fold: develop patient care strategies and antibiotic regimens that improve outcomes, reduce the likelihood of toxicity, and minimize the emergence of antibiotic resistance. Dr. Lodise is currently implementing epidemiological and outcomes research proposals at the Albany Medical Center Hospital and Stratton VA Medical Center, Albany, New York. He has published over 60 peer-reviewed articles in reputable scientific journals, including Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Chest, and Journal of Antimicrobial Chemotherapy. Dr. Lodise is a member of the Society of Infectious Diseases Pharmacists, the American Association of Colleges of Pharmacy, and American College of Clinical Pharmacist (ACCP). He is the editorial boards for Antimicrobial Agents and Chemotherapy, Pharmacotherapy, and Diagnostic Microbiology and Infectious Diseases.



<< Previous Abstract | Next Abstract

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.